Breast cancer biomarkers, and a new clinical category for HER2 expression

Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients

Identification of long-term survival-associated gene in breast cancer

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer - Laboratory Investigation

MLO LABline Daily - Feb 21st, 2024

Oncology

Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation, Egyptian Journal of Radiology and Nuclear Medicine

Scoring HER2 expression across the full spectrum - CAP TODAY

Determining breast cancer biomarker status and associated morphological features using deep learning

Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study

Cancer biomarker - Wikipedia

Treatment of HER2-Low, HR-Positive, and TNBC: A Focus on HER2-Targeted and TROP2–Targeted Therapy

Identifying ESR1 Mutations to Determine Resistance in HR+ Metastatic Breast Cancer- Cancer Therapy Advisor

Benefits and Applications of Oncotype DX Breast Recurrence Score Testing among Breast Cancer Patients: Current Recommendations and Controversies.

Clinical biomarkers for breast cancer.